Frontiers in Oncology (Jul 2023)

Rituximab in steroid-refractory immune-related pancreatitis: a case report

  • Armando Santoro,
  • Armando Santoro,
  • Silvia Masini,
  • Silvia Masini,
  • Raffaele Cavina,
  • Maria Chiara Tronconi,
  • Fabio De Vincenzo

DOI
https://doi.org/10.3389/fonc.2023.1205720
Journal volume & issue
Vol. 13

Abstract

Read online

The use of immune checkpoint inhibitors (ICIs) for treating several types of cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis is a rare irAE, mostly responsive to steroid treatment. There are no published data on the management of steroid-refractory ICI-induced pancreatitis. Rituximab has shown efficacy in the setting of relapsing non-ICI-induced autoimmune pancreatitis. However, its use has not been tested for treating immunotherapy-related pancreatitis. Here, we present the case of a patient with steroid-refractory immune-related pancreatitis successfully treated with rituximab as a potential strategy for irAE management.

Keywords